diosmin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3157 520-27-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • diosmin
  • barosmin
  • diosmil
  • diosmine
  • flebosten
  • flebosmil
A bioflavonoid that strengthens vascular walls.
  • Molecular weight: 608.55
  • Formula: C28H32O15
  • CLOGP: 0.23
  • LIPINSKI: 3
  • HAC: 15
  • HDO: 8
  • TPSA: 234.29
  • ALOGS: -2.60
  • ROTB: 7

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis and uveitis syndrome 70.51 38.55 10 912 166 50604036
Erysipelas 57.62 38.55 15 907 6593 50597609
Myoglobin blood increased 44.58 38.55 9 913 1284 50602918

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood lactic acid 94.28 44.94 14 517 332 29573664

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood lactic acid 86.17 30.43 14 1517 449 64496752
Tubulointerstitial nephritis and uveitis syndrome 63.06 30.43 10 1521 274 64496927
Erysipelas 53.21 30.43 16 1515 9065 64488136
Myoglobin blood increased 35.44 30.43 9 1522 2738 64494463
Lentigo maligna 31.83 30.43 6 1525 458 64496743

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C05CA03 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
CAPILLARY STABILIZING AGENTS
Bioflavonoids
ATC C05CA53 CARDIOVASCULAR SYSTEM
VASOPROTECTIVES
CAPILLARY STABILIZING AGENTS
Bioflavonoids
CHEBI has role CHEBI:22586 antioxidants
CHEBI has role CHEBI:67079 anti-inflammatory agents

Drug Use (View source of the data)

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.73 acidic
pKa2 10.43 acidic
pKa3 12.32 acidic
pKa4 13.05 acidic
pKa5 13.7 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase IC50 5.41 CHEMBL
Lysine-specific histone demethylase 1A Enzyme IC50 4.99 CHEMBL

External reference:

IDSource
N0000167025 NUI
D07858 KEGG_DRUG
4036523 VANDF
C0012498 UMLSCUI
CHEBI:4631 CHEBI
CHEMBL231884 ChEMBL_ID
D004145 MESH_DESCRIPTOR_UI
DB08995 DRUGBANK_ID
4370 INN_ID
7QM776WJ5N UNII
5281613 PUBCHEM_CID
3489 RXNORM
005803 NDDF
126142004 SNOMEDCT_US
8143001 SNOMEDCT_US

Pharmaceutical products:

None